Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.61 |
| ▸ | CCR8 | P51685 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 4/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1456112 | 0.88 | CCR1 (0.80) | CCR1CCR8LMNAMETAP2CYP2A6 | |
| SCHEMBL1456390 | 0.88 | CCR1 (0.80) | CCR1CCR8LMNAMETAP2CYP2A6 | |
| SCHEMBL1456176 | 0.88 | CCR1 (0.80) | CCR1CCR8LMNAMETAP2CYP2A6 | |
| SCHEMBL13080532 | 0.87 | LMNA (0.44) | CCR1CCR8LMNAMETAP2MAOB | |
| SCHEMBL5291610 | 0.86 | CCR1 (0.70) | CCR1CCR8LMNAMETAP2CYP2A6 | |
| SCHEMBL4182284 | 0.86 | CCR1 (0.70) | CCR1CCR8LMNAMETAP2CYP2A6 | |
| SCHEMBL4184174 | 0.86 | CCR1 (0.70) | CCR1CCR8LMNAMETAP2CYP2A6 | |
| SCHEMBL3753156 | 0.86 | CCR1 (0.76) | CCR1CCR8LMNAMETAP2CYP2A6 | |
| SCHEMBL3744881 | 0.86 | LMNA (0.43) | CCR1CCR8LMNAMAOBKMT2A | |
| SCHEMBL16715989 | 0.86 | CCR1 (0.76) | CCR1CCR8LMNAMETAP2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069345-A2 | PYRIDAZINE AND PYRROLE COMPOUNDS, PROCESSES FOR OBTAINING THEM AND USES | Centre National de la Recherche Scientifique (CNRS) (FR) | 2009-06-17 | — | — | EP | claimed |
| WO-2008012440-A2 | PYRIDAZINE AND PYRROLE COMPOUNDS, PROCESSES FOR OBTAINING THEM AND USES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2008-01-31 | — | — | WO | claimed |
| US-9034873-B2 | Pyridazine and pyrrole compounds, processes for obtaining them and uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2015-05-19 | — | — | US | disclosed |
| US-20100298562-A1 | Pyridazine and Pyrrole Compounds, Processes For Obtaining Them and Uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2010-11-25 | — | — | US | disclosed |
| EP-2069345-A2 | PYRIDAZINE AND PYRROLE COMPOUNDS, PROCESSES FOR OBTAINING THEM AND USES | Centre National de la Recherche Scientifique (CNRS) (FR) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008012440-A2 | PYRIDAZINE AND PYRROLE COMPOUNDS, PROCESSES FOR OBTAINING THEM AND USES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298562-A1 | Pyridazine and Pyrrole Compounds, Processes For Obtaining Them and Uses | PPOX, PNPO, PLPBP | CCR1 3696/4885CCR8 3435/4885LMNA 4332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.